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Abstract
Background: The prevalence of smoking among people living with HIV (PLHIV) is higher than that reported in the general
population, and it is a significant risk factor for noncommunicable diseases in this group. Mobile phone interventions to promote
healthier behaviors (mobile health, mHealth) have the potential to reach a large number of people at a low cost. It has been
hypothesized that mHealth interventions may not be as effective as face-to-face strategies in achieving smoking cessation, but
there is no systematic evidence to support this, especially among PLHIV.
Objective: This study aimed to compare two modes of intervention delivery (mHealth vs face-to-face) for smoking cessation
among PLHIV.
Methods: Literature on randomized controlled trials (RCTs) investigating effects of mHealth or face-to-face intervention
strategies on short-term (4 weeks to <6 months) and long-term (≥6 months) smoking abstinence among PLHIV was sought. We
systematically reviewed relevant RCTs and conducted pairwise meta-analyses to estimate relative treatment effects of mHealth
and face-to-face interventions using standard care as comparison. Given the absence of head-to-head trials comparing mHealth
with face-to-face interventions, we performed adjusted indirect comparison meta-analyses to compare these interventions.
Results: A total of 10 studies involving 1772 PLHIV met the inclusion criteria. The average age of the study population was
45 years, and women comprised about 37%. In the short term, mHealth-delivered interventions were significantly more efficacious
in increasing smoking cessation than no intervention control (risk ratio, RR, 2.81, 95% CI 1.44-5.49; n=726) and face-to-face
interventions (RR 2.31, 95% CI 1.13-4.72; n=726). In the short term, face-to-face interventions were no more effective than no
intervention in increasing smoking cessation (RR 1.22, 95% CI 0.94-1.58; n=1144). In terms of achieving long-term results among
PLHIV, there was no significant difference in the rates of smoking cessation between those who received mHealth-delivered
interventions, face-to-face interventions, or no intervention. Trial sequential analysis showed that only 15.16% (726/1304) and
5.56% (632/11,364) of the required information sizes were accrued to accept or reject a 25% relative risk reduction for short- and
long-term smoking cessation treatment effects. In addition, sequential monitoring boundaries were not crossed, indicating that
the cumulative evidence may be unreliable and inconclusive.
Conclusions: Compared with face-to-face interventions, mHealth-delivered interventions can better increase smoking cessation
rate in the short term. The evidence that mHealth increases smoking cessation rate in the short term is encouraging but not sufficient
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to allow a definitive conclusion presently. Future research should focus on strategies for sustaining smoking cessation treatment
effects among PLHIV in the long term.
(JMIR Mhealth Uhealth 2019;7(1):e203)   doi:10.2196/mhealth.9329
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Introduction
The introduction of effective antiretroviral therapy has resulted
in a marked reduction in AIDS-related mortality worldwide.
Patterns of morbidity and mortality have shifted from
AIDS-related opportunistic infections to age-related
comorbidities; moreover, it is now recognized that people living
with HIV (PLHIV) are at increased risk of developing
cardiovascular disease [1,2]. This increased risk is likely to be
of multifactorial origin [3]: the disease and its treatment.
Moreover, PLHIV are predisposed to engage in unhealthy
behaviors [1,2].
Tobacco use is the single most common cause of preventable
death worldwide and an important modifiable risk factor for
several chronic conditions, including coronary heart diseases,
chronic obstructive pulmonary diseases, and certain cancers [4].
About 15% of the world’s population smoked tobacco in 2015
[5]. However, prevalence estimates of tobacco use in vulnerable
populations are much higher: 32% among people with mental
health disorders [6], 73% among homeless people [7], 77%
among substance abusers [8], and 84% among prisoners [9]. Of
note, the prevalence of smoking in PLHIV ranges between 50%
and 70% [10], and like other vulnerable groups, success rates
of quitting attempts and sustained abstinence are much lower
than in the general population [11]. Smoking for stress relief,
inadequate support from health service providers, and high
smoking acceptance rates among communities of PLHIV are
among the perceived barriers to abstinence in this high-risk
group, and these considerably differ from self-reported barriers
in apparently healthy populations without known chronic
conditions [11]. For these reasons, intervention strategies for
smoking cessation in the general population may not be as
effective in HIV-positive populations. Although there have been
several reports on the effectiveness of smoking cessation
interventions among PLHIV [12], there are still questions left
unanswered, notably about the mode of intervention delivery
and its impact on smoking cessation. Short message service
(SMS) text messages and other phone-based strategies have the
potential to be more cost effective in service delivery than
face-to-face contact, but it has been hypothesized that such
mobile health (mHealth) strategies might be less effective or
no different in terms of achieving smoking abstinence [12].
mHealth services provide unique opportunities for delivering
smoking cessation interventions to large number of people at a
low cost. However, there is no systematic evidence to
substantiate this hypothesis. Therefore, we first sought to review
all existing literature investigating mHealth and face-to-face
interventions for smoking cessation among PLHIV. Second,
we examined whether the required amount of information has
been reached to confidently conclude that mHealth is more
effective than no mHealth and that future trials need not examine
this question any longer.
Methods
Information Sources and Search Strategy
We conducted searches on the following major databases:
Embase, Medical Literature Analysis and Retrieval System
Online, the Cochrane Library Central Register of Controlled
Trials, the ClinicalTrials.gov registry, and cross-references of
relevant articles for randomized controlled trials (RCTs)
investigating the effectiveness of smoking cessation
interventions among HIV-positive smokers and published until
up to May 2018. Multimedia Appendix 1 shows the database
search strategy, including the search term combinations used.
Selection Criteria
We evaluated each identified study against the following
predetermined selection criteria: Types of population (PLHIV);
types of intervention and comparator (face-to-face counseling,
mHealth-delivered intervention, or no intervention country
group); types of outcome (smoking abstinence); and study design
(RCTs).
Selection of Studies
Two authors (CUN and MA) screened the titles and abstracts
of all the potential studies we identified as a result of the search
and coded them as “retrieve” (eligible or potentially eligible or
unclear) or as “do not retrieve.” Any disagreements were
arbitrated by a third author (OAU). Subsequently, CUN and
MA assessed the full-text study reports to confirm their
eligibility for inclusion while noting the reasons for excluding
studies considered ineligible for the meta-analysis. Again, any
disagreements were resolved following discussions with OAU.
Data Extraction
CUN and MA extracted demographic and clinical data from the
included studies where available. Data on trial design, sample
size, mean age, proportion of women, average daily number of
cigarettes, interventions, outcomes, and follow-up durations
were extracted. Any disagreements were resolved following
discussions with OAU.
Outcome Measures
The main outcome was short-term smoking abstinence, which
has been defined as abstinence of at least 4 weeks duration, but
less than 6 months after the intervention was initiated [12]. The
secondary outcome was smoking abstinence of at least 6 months
duration (long-term abstinence) [13].
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Risk of Bias Assessment
CUN and MA judged the risk of bias in each included study
using the Cochrane risk of bias assessment tool, which includes
the following domains: randomization sequence generation
(selection bias); allocation concealment (selection bias); blinding
of participants, providers, (performance bias) and outcome
assessors (detection bias); completeness of outcome data
(attrition bias); and selective outcome reporting (reporting bias).
Each RCT was classified as having “high,” “low,” or “unclear”
risk of bias in each domain [14]. OAU resolved any differences
in the assessments.
Statistical Analysis
We adopted an adjusted indirect comparison meta-analysis
[15-18], a logical extension of standard meta-analysis to infer
relative effectiveness of mHealth-delivered versus face-to-face
interventions when the direct “head-to-head” evidence is lacking,
that is, not directly addressed within any of the included trials.
To illustrate this, in a situation where we have 3 treatments A
(mHealth), B (face-to-face), and C (no intervention control), A
and C have been compared in RCTs; B and C have been
compared in other RCTs; and A and B had not been directly
compared. The approach enabled the indirect comparisons (eg,
A vs B) constructed from 2 trials that have one treatment in
common to be incorporated (eg, A vs C and B vs C; Figure 1).
Using Bucher adjusted indirect comparison method, the
treatment effect for TAB can be calculated by using the following
equation:
TAB=TAC–TBC
where T represents the treatment effect (eg, log risk ratio, RR)
between the 2 interventions. SE is calculated as follows:
SE(TAB)=√(SE(TAC)
2–SE(TBC)
2)
All data were analyzed using R package “stats” (version 3.2.2).
As part of the primary analysis, subgroup analysis was
conducted based on the intensity and duration of follow-up
period. Analysis was performed separately for short-term (4
weeks to <6 months) and long-term (≥6 months) smoking
abstinence. We also quantified heterogeneity by computing the
I2 statistic; a value greater than 50% implied that the treatment
estimates were considerably heterogeneous across the included
studies. The pooled treatment estimates were reported using
RRs and 95% CIs.
We examined the reliability and conclusiveness of the available
evidence using trial sequential analyses (TSA) [19-21]. The
sample size required for a reliable and conclusive meta-analysis
is at least as large as that of a single optimally powered RCT.
Therefore, we calculated the sample size (ie, the
heterogeneity-corrected optimal information size) required to
detect or reject a minimal 25% relative risk reduction
intervention effect. We then used the heterogeneity-corrected
optimal information size to help construct Lan-DeMets
sequential monitoring boundaries for our cumulative
meta-analyses [22], analogous to interim monitoring in an RCT,
to determine when sufficient evidence had been accrued (Figure
2): Significant (P<.05) meta-analysis included potentially
spurious evidence of effect, that is, the cumulative Z-curve did
not cross the monitoring boundaries (curve A), or firm evidence
of effect, that is, the cumulative Z-curve crossed the monitoring
boundaries (curve B). Nonsignificant (P ≥.05) meta-analysis
included absence of evidence, that is, the meta-analysis included
less patients than the required information size (curve C), or
lack of effect, that is, the meta-analysis included more patients
than the required information size (curve D). We conducted
TSA using TSA version 0.937 with an intention to maintain an
overall 5% risk of a type I error and 20% risk of a type II error
(power of 80%).
Figure 1. Adjusted indirect comparison network meta-analysis framework. A: mhealth delivered; B: face to face; C: standard of care.
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Figure 2. Trial sequential analysis.
Results
Study Selection and Characteristics of Included Studies
The study selection process is illustrated in Figure 3. The search
strategy yielded 308 records, and upon screening abstracts and
duplicate records, we identified 23 potentially eligible studies.
We excluded 13 additional studies for the following reasons:
the outcome was not abstinence (4 studies), no control group
existed (4 studies), follow-up was less than 4 weeks (1 study),
the study was quasi-experimental (1 study), face-to-face or
mHealth interventions were not specified (1 study), a zero
smoking abstinence rate was found in both the intervention and
control groups, a computational error was identified (1 study),
and participants in the intervention arm received either mHealth
or face-to-face interventions but not both (1 study). Hence, 10
RCTs met the inclusion criteria and were included in the analysis
[23-32].
The 10 included studies comprised a total of 1772 participants,
all of whom were current smokers living with HIV. All studies
were from a high-income country, that is, the United States
(Table 1). On average, each participant at baseline smoked about
16 cigarettes daily (range 11-20). The average age of the study
population was 45 years (range 42-50), and women comprised
about 37% (range 8%-100%). Smoking cessation strategies
were administered face-to-face in 7 studies [23-27,29,30], and
sustained smoking abstinence estimates were reported in 4
studies [23,30-32]. The intensity and maximum follow-up period
ranged from 4 weeks to as much 52 weeks. The number of
counseling also varied across the studies, from 1 session to 11
sessions.
Risk of Bias in Included Studies
Among the 10 included studies, 6 reported the use of
computer-generated lists of random numbers for randomization,
whereas the other 4 studies did not describe the random sequence
generation process. Allocation concealment was not described
in any study; therefore, the risks of selection bias were unclear.
Blinding of the participants and investigators was not described
in 9 of the 10 studies, leaving 1 study in which investigators
facilitated counseling sessions, which was thus judged to have
a high risk of performance bias. Outcomes assessors were
masked to the intervention in 2 studies, whereas the other 8
studies were assessed to have unclear risks of detection bias.
Attrition bias was low in 7 studies, and reporting bias high or
unclear in 5 studies (Figure 4).
Short-Term Smoking Cessation (4 Weeks to <6
Months)
Figure 5 displays a caterpillar plot of the relative RRs and 95%
CIs of efficacy for all possible pairwise comparisons of the
different treatment strategies. For short-term smoking cessation
(ie, ≥4 weeks of smoking abstinence within 6 months of the
intervention), 7 trials compared face-to-face intervention versus
no intervention control group, and 4 compared
mHealth-delivered interventions versus no intervention control
group (n=1870). Participants randomized to SMS-delivered
interventions were 2.81 times more likely to have stopped
smoking compared to those who received standard care (RR
2.81, 95% CI 1.44-5.49). In addition, PLHIV who received
mHealth-delivered interventions were twice as likely to have
stopped smoking compared to those who received face-to-face
interventions (RR 2.31, 95% 1.13-4.72). On average,
face-to-face interventions were no more effective than no
intervention in increasing short-term smoking cessation (RR
1.22, 95% CI 0.94-1.58). The measure of inconsistency between
studies (I2) was 6.3%, suggesting that the included studies were
not statistically heterogeneous.
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Figure 3. Study selection flow diagram. SMS: short message service.
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Table 1. Characteristics of the included studies.
Follow-up durationsOutcomeInterventionAverage daily
number of
cigarettes
Women
(%)
Average
age,
years
Sample
size
Study
12, 24, 26, and 52
weeks
Sustained smoking
abstinence
1 face-to-face CBTb ses-
sion and 6 face-to-face
CBT sessions
19.81845209Humfleet 2015 [23]
4 and 12 weeks7-day point preva-
lence smoking absti-
nence
1 face-to-face counseling
session
17.3454240Ingersoll 2009 [24]
2, 4, and 6 months7-day point preva-
lence smoking absti-
nence
4 face-to-face counseling
sessions
18.23742444Lloyd-Richardson 2009 [25]
4 weeks7-day point preva-
lence smoking absti-
nence
1 face-to-face counseling
session
16.11004930Manuel 2013 [26]
42 and 132 days7-day point preva-
lence smoking absti-
nence
8 face-to-face counseling
sessions
12.05149145Moadel 2012 [27]
1, 4, 8, 12, and 24
weeks
7-day point preva-
lence smoking absti-
nence
Twice daily short mes-
sage service text mes-
sages and twice daily
short message service
text messages+7 phone
counseling sessions
15.01650158Shelley 2015 [28]
6 weeks, 3 months7-day point preva-
lence smoking absti-
nence
8 face-to-face CBT ses-
sions
10.94046138Shuter 2014 [29]
3 monthsSustained smoking
abstinence
Face-to-face counseling13.0842.940Tucker 2017 [30]
3 monthsSustained smoking
abstinence
8 phone counseling ses-
sions
20.1224394Vidrine 2006 [31]
3, 6, and 12 monthsSustained smoking
abstinence
11 phone counseling ses-
sions
19.23045474Vidrine 2012 [32]
aRCT: randomized controlled trial.
bCBT: cognitive behavioral therapy.
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Figure 4. Risk of bias in included studies.
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Figure 5. Pairwise comparisons of all interventions, short-term effect. RR: risk ratio; SMS: short message service; SoC: standard of care, no intervention
control.
Figure 6. Trial sequential analysis for mHealth for smoking cessation in people living with HIV, short-term effect. mHealth: mobile health.
Our calculations indicated that the optimal information size
needed to reliably detect a plausible treatment effect for
short-term smoking cessation is 4797 participants (Figure 6).
However, only 15.16% (726/4787) of the participants of the
required information size were accrued. More so, the sequential
monitoring boundary has not been crossed, indicating that the
cumulative evidence is unreliable and inconclusive (Figure 6).
Long-Term Smoking Cessation (≥6 Months)
For long-term smoking cessation, that is, abstinence ≥6 months,
3 trials compared face-to-face intervention versus no
intervention control group and 2 compared mHealth-delivered
interventions versus no intervention control group (n=1546).
There was no significant difference in smoking cessation rates
between PLHIV randomized to mHealth-delivered interventions
and those in the no intervention control group (RR 0.67, 95%
CI 0.27-1.67). Similarly, there was no significant difference in
smoking cessation rates between face-to-face interventions and
no intervention control groups (RR 1.02, 95% CI 0.68-1.53).
In addition, adjusted indirect treatment comparison between
face-to-face and mHealth interventions revealed no significant
difference (RR 0.65, 95% CI 0.29-1.47; Figure 7). The measure
of inconsistency between the included studies (I2) was 0%,
suggesting no evidence that the included studies were
statistically heterogeneous.
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Figure 7. Pairwise comparisons of all interventions, long-term effect. RR: risk ratio; SMS: short message service; SoC: standard of care, no intervention
control.
Figure 8. Trial sequential analysis for mHealth for smoking cessation in people living with HIV, long-term effect. mHealth: mobile health.
Our calculations indicated that the optimal information size
needed to reliably detect a plausible treatment effect for
long-term smoking cessation was 11,364 participants (Figure
8). However, only 5.56% (632/11,364) participants of the
required information size were accrued in the pooled analysis.
The sequential monitoring boundary has also not been crossed,
indicating that the cumulative evidence is unreliable and
inconclusive (Figure 8).
In Figure 8, dashed blue cumulative Z curves do not cross solid
black trial sequential monitoring boundaries for benefit and
horizontal red lines illustrate the traditional level of statistical
significance (P=.05).
Discussion
Principal Findings
The results suggest that mHealth interventions for smoking
cessation in PLHIV leads to better short-term improvement in
smoking cessation rates than face-to-face interventions.
However, from 6 months after the intervention and onward,
there is no evidence of any effect regardless of the mode of
intervention delivery. Our findings are broadly consistent with
a previous meta-analysis of studies conducted in the general
population, which reported a higher pooled smoking abstinence
rate associated with SMS text messaging for 3 months compared
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to SMS text messaging for 6 months [33]. It is important to note
that the absence of evidence is not evidence of absence of
long-term effects of mHealth-delivered interventions. The lack
of significant differences in long-term abstinence, however,
may be due to the small number of studies contributing to this
indirect evidence network, and as such, the evidence is
inconclusive. Accurate understanding of the strength of the
evidence for mHealth requires a systematic, comprehensive,
and unbiased accumulation of the available evidence and
methods adopted from formal interim monitoring boundaries
applied to cumulative meta-analysis. The results of our TSA
showed that the evidence that mHealth increases smoking
cessation rates in the short term is encouraging but may be
unreliable to make conclusive inferences.
Given the crucial need for the prevention of cardiovascular
disease risk in PLHIV, there is a need for future pragmatic trials
comparing mHealth and face-to-face intervention, especially in
resource-limited settings that bear the highest burden of HIV
and where smoking is now a bigger problem [2,34].
Furthermore, low-income settings are now experiencing an
epidemiological transition from infectious diseases to chronic
diseases [2] as a result of dramatic changes in diet and lifestyle.
The epidemiological transition in resource-limited settings is
happening over a shorter time frame than that experienced
historically by high-income countries [34]. In addition, there is
a need to identify mHealth-delivered interventions that are most
beneficial for PLHIV. We should also investigate innovative
specific features of mHealth interventions that can achieve
long-term effects, for example, by varying the mode of delivery
(weekly SMS text messaging) or by personalized and more
tailored SMS text messages.
Limitations
The limitations in our study warrant consideration. First, the
included studies were conducted in a high-income setting, which
potentially limits generalization of the results to low- and
middle-income settings in which the burden of HIV and
tobacco-related illnesses and deaths are currently most severe
[5]. Nonetheless, our findings may be generalizable to other
vulnerable groups in high-income countries. Second, the
intervention arms in the included studies all comprised
multicomponent strategies, which may have influenced our
results; however, tests for heterogeneity revealed that the studies
included in our analyses were in fact homogeneous. Third, we
could not compare mHealth or face-to-face interventions with
strategies that entailed a combination of both interventions
because none of the included studies allowed this dual treatment
in the intervention arm. Wewers et al [35] examined mHealth
and face-to-face interventions in their study; however, we
considered this study ineligible because the participants received
either mHealth or face-to-face interventions and not both and
because the numbers were not specified. Furthermore, with only
10 studies considered eligible for our review, we could not
perform meta-regression analyses to explore potential
effect-modifiers such as age, sex, coexisting substance abuse,
and average number of cigarettes smoked daily at baseline. In
spite of these limitations, we present novel systematic evidence
evaluating the preferred mode of contact to be employed for
improving smoking abstinence among PLHIV.
Conclusion
Compared to face-to-face interventions, mHealth-delivered
interventions can boost smoking cessation rates, at least in the
short term, among PLHIV with higher smoking prevalence rates
than the general population. However, it remains unclear how
long the effects of such interventions last. Future research should
focus on strategies for sustaining the treatment effect in the long
term and move beyond high-income settings.
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